By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asterand said today that it has won a contract from the National Institutes of Health valued at up to $24.3 million to support The Cancer Genome Atlas program.

Under the National Cancer Institute contract, which gives Asterand $5.4 million over a 17-month period and includes an option for renewal, the firm will supply clinically annotated human biospecimens to NCI for use in TCGA projects.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.